The role of microRNAs in congenital heart disease by Nagy, Orsolya et al.
eJIFCC2019Vol30No2pp165-178
Page 165
In this issue: Non-coding RNAs as potential laboratory biomarkers
This is a Platinum Open Access Journal distributed under the terms of the Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The role of microRNAs 
in congenital heart disease
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A R T I C L E  I N F O A B S T R A C T
Congenital heart diseases (CHDs) are the leading in-
herited cause of perinatal and infant mortality. CHD 
refers to structural anomalies of the heart and blood 
vessels that arise during cardiac development and 
represents a broad spectrum of malformations, in-
cluding septal and valve defects, lesions affecting the 
outflow tract and ventricules. Advanced treatment 
strategies have greatly improved life expectancy and 
led to expanded population of adult patients with 
CHD. Thus, a better understanding of the pathogen-
esis and molecular mechanisms underlying CHDs is 
essential to improve the diagnosis and prognosis of 
patients. The etiology of CHD is largely unknown, ge-
netic and environmental factors may contribute to 
the disease. In addition to the mutations affecting ge-
nomic DNA, epigenetic changes are being increasing-
ly acknowledged as key factors in the development 
and progression of CHDs. The posttranscriptional 
regulation of gene expression by microRNAs (miRs) 
controls the highly complex multi-cell lineage pro-
cess of cardiac tissue formation. In recent years, mul-
tiplex experimental models have provided evidence 
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that changes in expression levels of miRs are as-
sociated with human cardiovascular disease, in-
cluding CHD. The newly described correlations 
between miRs and heart development suggest 
the potential importance of miRs as diagnostic 
markers in human cardiovascular diseases. In 
the future, more intensive research is likely to 
be carried out to clarify their contribution to 
personalized management and treatment of 
CHD patients. In this paper, we discuss the cur-
rent knowledge on the causative role of miRs in 
cardiac development and CHDs.

INTRODUCTION
CHD defines functional and structural disorders 
of the heart and blood vessels that arise during 
embryogenesis. CHD is the most common cause 
of perinatal and infant mortality. The reported 
birth prevalence varies widely across countries 
and continents, the best estimation generally 
accepted is 8 per 1,000 live births (1). CHDs 
are the leading cause of infant morbidity and 
mortality and account for approximately 40% 
of prenatal deaths and 20% of mortality in the 
first year of life (2, 3). CHDs encompass a wide 
spectrum of phenotypes including atrial septal 
defect (ASD), ventricular septal defect (VSD), 
patent ductus arteriosus (PDA), transposition 
of the great arteries (TGA), pulmonary valve 
atresia (PVA), coarctation of the aorta (CoA), 
tricuspid atresia (TA), tetralogy of Fallot (TOF), 
hypoplastic left heart syndrome (HLHS) and 
univentricular heart (UH). The severity of the 
different forms of CHD varies extensively from 
simple mild lesions with follow-up for decades 
without any treatment to complex cyanotic 
malformations requiring urgent surgical inter-
vention (4). Recent advances in pre- and post-
natal diagnosis as well as surgical treatment 
approaches have increased life expectancy of 
patients with CHD. Nowadays more than 75% of 
CHD patients live to adulthood, increasing the 
pediatric CHD cohort and requiring lifelong spe-
cialized cardiac care. As a result, an increased 
number of patients will reach the reproductive 
age and can transmit the disease with a high 
risk (5, 6). Therefore, a better understanding of 
the etiology is essential in order to give early 
diagnosis, allow timely interventions, effective 
patient management and proper genetic coun-
seling. To date, approximately 20% of CHD cases 
have known causes, such as teratogen effects 
or genetic alteration. Half of the genetic abnor-
malities are chromosomal aneuploidy, submi-
croscopic copy number variation or nucleotide 
sequence mutations. These abnormalities may 
cause syndromes (with extracardiac symptoms) 
or isolated heart defects. Clarification of genet-
ic background is complicated due to low pen-
etrance, high phenotypic variability and vari-
able expression of symptoms (7, 8). Very little is 
known about the etiology of the remaining 80% 
of cases, most of them follow multifactorial in-
heritance including genetic and environmental 
factors in disease development (7). Recently, 
epigenetics is being increasingly acknowl-
edged as a key mechanism in the pathophysiol-
ogy of cardiovascular diseases, including CHDs. 
Epigenetics refers to a set of mechanisms that 
regulate gene expression without changing the 
underlying nucleotide sequence. Beside DNA 
methylation and histone modification as two 
basic elements of epigenetic machinery, non-
coding RNA (ncRNA) molecules can also induce 
epigenetic modifications by post-transcriptional 
regulation of gene expression. The best studied 
group of noncoding RNAs are miRs, which are 
small, evolutionarily conserved, single-stranded 
RNA molecules, approximately 22 nucleotides 
in length at mature stage. They suppress ex-
pression of target genes by inhibiting transla-
tion or encouraging degradation of their mRNA 
by complementary base pairing at 3’UTR. The 
degree and nature of complementary sites 
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between the miR and target mRNA appear to 
determine the gene silencing mechanism. Since 
the first description in the early 1990s, more 
than 1000 miRs have been identified in mam-
mals regulating more than 30% of genes. A 
single miR can regulate multiple target mRNAs, 
and individual mRNA can be targeted by many 
miRs (2, 9, 10).
The aim of this paper is to review the current 
knowledge of the potential role of miRs in ab-
normal cardiac development and consequently 
in CHD.
THE ROLE OF MICRORNAS  
IN HEART DEVELOPMENT
Various roles of miRs were identified in the 
pathogenesis, progression, and remodeling of 
cardiovascular diseases. The process of cardiac 
tissue formation and cardiac gene expression 
is so highly complex that it requires formation 
of diverse cell types, including cardiomyocytes, 
valvular and endothelial cells, conduction sys-
tem, smooth muscle cells, in a tightly regulated, 
spatiotemporal manner. MiRs increase this com-
plexity even further by adding another layer of 
regulation at the post-transcriptional level (11, 
12). The significance of miRs in cardiogenesis 
was first revealed in gene deletion experiments 
in animal models, using mice and zebrafish.
Dicer is an essential endonuclease in the miR 
biogenesis pathway, disruption of its function 
removes all mature miRs. Dicer deletion in 
mice and mutation in zebrafish caused lethality 
by arresting gastrulation, providing convincing 
evidence on the essential role of miRs in early 
animal development. To better understand the 
function of miRs in cardiac tissues, studies on 
tissue specific Dicer deletion were carried out 
on mouse heart at different developmental 
stages. Deletion of cardiac specific Dicer pre-
natally resulted in defective heart morphogen-
esis and embryonic lethality. However, heart 
specific Dicer deletion after birth led to abnor-
mal expression of contractile proteins, and re-
markable sarcomere disarray coupled with re-
duced cardiac function and rapid progression 
to dilated cardiomyopathy and heart failure. 
This cardiac phenotype closely resembled hu-
man dilated cardiomyopathy and heart failure 
(13-15). To understand the contribution of in-
dividual miRs to cardiac development, much 
research has been undertaken with gain- and 
loss-of-function studies of specific miRs (16-18). 
The outcomes of these studies clearly indicated 
that single miRs have crucial roles in cardiac de-
velopment and function.
MiR-1 (miR-1-1, miR-1-2, miR-206) and miR-133 
(miR-133a-1, miR-133a-2, miR-133b) families 
are highly conservative. They are abundantly, 
but not exclusively expressed in the heart. These 
miRs are produced from the same polycistronic 
transcript, encoded by two separate genes in 
the mouse and human genomes, therefore they 
have identical sequences and consequently tar-
get the same mRNAs.
Last decades of intensive research using devel-
opmental models of the heart have revealed 
that these miRs control fundamental cardiac 
transcription factors, such as GATA4, TBX1, 
MEF2C, SRF and MHC genes. MiR-1/-133 have a 
crucial role in regulation of cardiomyocyte pro-
liferation. They are also known to induce me-
soderm formation and differentiation of embry-
onic stem cells. In the developing mouse heart, 
excessive expression of miR-1 inhibited ventric-
ular myocyte proliferation (17).
In contrast, targeted deletion of miR-1-2 was 
found to be lethal at nearly 50% of mouse 
embryos at weaning age, and some animals 
showed ventricular septal or conduction system 
defects in later stage (18). Deletion of either 
miR-133a-1 or miR-133a-2 did not affect seri-
ously the cardiogenesis, but resulted in VSD and 
chamber dilatation leading to late embryonic or 
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early postnatal death (19). Both miR-1 and miR-
133 seemed to regulate growth-related car-
diac genes as growth suppressors and had an 
opposite role in cardiomyocyte apoptosis (20, 
21). Furthermore, miR-1 was linked to NOTCH1 
receptor, whose ligand is essential in normal 
asymmetric division (22). To understand the ex-
act molecular mechanism underlying the func-
tion of miRs, their target genes are required to 
be identified. In case of miR-1, one important 
validated target is Hand2 cardiac transcription 
factor. Deletion of Hand2 gene in mouse models 
leads to similar failure in ventricular myocytes 
as miR-1 overexpression, which also reduces ex-
pression of Hand2 (17).
The miR-15 family includes six miRNAs: miR-
15a, miR-15b, miR-16-1, miR-16-2, miR-195, 
miR-497. By inhibiting these miRs, mitosis of 
myocardial cells increases and the suppression 
of the most important target gene, CHEK1 is 
eliminated. Of particular importance is the miR-
195, whose overexpression was detected dur-
ing cardiac hypertrophy in human and mouse 
hearts, and it was sufficient alone to induce 
hypertrophic growth of cultured rat cardiomyo-
cytes (23).
MiRs belonging to the miR-208 family (miR-208a, 
miR-208b, miR-499) are commonly referred to 
as MyomiRs, expressed specifically in the heart. 
MiR-208-null animals do not show gross devel-
opmental defects although their overexpres-
sion induces cardiac hypertrophy and conduc-
tion defects (24). Among their target genes, the 
THRAP1 is involved in the negative regulation of 
myocardial growth and hypertrophy. MiR-499 is 
responsible for the expression of myosin genes 
in the heart muscle of mice (24-26).
The 17-92 miRs are clustered, and initially 
they were known as oncogenes (oncomiR). A 
few of these miRs (miR-17, miR-18a, miR-19a, 
miR-19b-1, miR-20a, miR-92a-1) play an impor-
tant role in cardiogenesis, participating in the 
differentiation of progenitor cells in the heart 
muscle. Their elevated level causes CHDs due 
to inhibition of the expression of the main pro-
genitor genes (ISL1, TBX1) (12).
The miR-143 family expressed in endocardial, 
myocardial and cardiac progenitor cells is in-
volved in the regulation of the ADD3 target 
gene, which encodes the F-actin capping pro-
tein. This pathway is involved in the proper 
design and function of the heart chambers. 
By knocking out these miRs, outflow tract or 
ventricular disorders can develop in the heart 
(27, 28).
Evolutionarily conserved miR-218a-1, miR-
218a-2 and miR-218b together with SLIT2 and 
ROBO genes provide the adequate develop-
ment of the heart tube. Together with the tran-
scription factor TBX5, they participate in the 
morphogenesis of the heart. Downregulation of 
miR-218 causes overexpression of TBX5, result-
ing in heart looping and chamber disorders (29).
ALTERED MICRORNA EXPRESSIONS 
IN CONGENITAL HEART DISEASES 
AND THEIR USE AS BIOMARKERS
During the past decade, findings of miR expres-
sion profiling experiments have demonstrated 
that significant changes of specific miR signa-
tures occur in various forms of cardiovascular 
diseases, including CHDs (22). The first studies 
documented deregulated miR expression pat-
terns in humans mostly in the myocardial tis-
sues, such as ventricular myocardium or outflow 
tract tissues (2, 10, 30). Subsequently, it became 
clear that some miRs released from their cells 
of origin can also be detected in different bodily 
fluids (31-33). Numerous studies started to in-
vestigate tissue- and disease-specific miR pro-
files in bodily fluids in different human patho-
logical conditions (34-36). Extracellular miRs 
became attractive candidates as noninvasive 
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Sample CHD Control
Methods MicroRNAs
Refer-
ence
Screening
Confirma-
tory
Candi-
date
Confirmed
Expres-
sion
Cardiac 
tissue
TOF 
(n=16)
n=8 
normally 
developing 
hearts
Microarray RT-qPCR miRs 
(n=61)
miR-27b 
miR-421 
miR-1275
Upregu-
lated
(10)
miR-122 
miR-1201
Downregu-
lated
Cardiac 
tissue
TOF 
(n=21)
n=6 
normal 
controls
Microarray RT-qPCR miRs 
(n=41)
miR-19a 
miR-130b 
miR-146b-5p 
miR-154 
miR-155 
miR-181c 
miR-181d 
miR-192 
miR-222 
miR-337-5p 
miR-363 
miR-424 
miR-424* 
miR-660 
miR-708
Upregu-
lated
(30)
miR-29c 
miR-181a* 
miR-720
Downregu-
lated
Table 1 MicroRNA profiling methods and expression changes in CHD*
biomarkers for early diagnosis or prognosis of 
CHDs (34, 37, 38) (Table 1).
However, extracellular miR profiling as a valid 
diagnostic or prognostic tool is still in the de-
scriptive phase. The highly variable miR assess-
ments from blood are derived from the dif-
ferent extraction methods, analysis platforms 
applied and the fact that the extracellular miRs 
are either associated with proteins or contained 
in cellular fragments (e.g. microparticles, exo-
somes). An excellent review summarizes the 
currently used methodological approaches in 
utilizing miRs as circulating biomarkers.
The authors highlighted optimal miR isolation 
protocols, the advantages and disadvantages 
of various expression methods and provided a 
workflow in designing miR profiling from plas-
ma or serum samples (39).
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Cardiac 
tissue
VSD 
(n=28)
n=9 
normal 
heart 
tissues
Microarray RT-qPCR miRs 
(n=25)
miR-181c
Upregu-
lated
(41)
miR-1-1
Downregu-
lated
Cardiac 
tissue
TOF 
(n=16)
n=8 
normally 
developing 
hearts
Microarray RT-qPCR miRs 
(n=61)
miR-421
Upregu-
lated
(44)
Cardiac 
tissue
TOF 
(n=26)
n=15 
healthy in-
dividuals
Microarray RT-qPCR miRs (n=75) miR-940
Downregu-
lated
(46)
Cardiac 
tissue
HLHS 
(n=15)
n=6 
non-failing 
control 
hearts
Microarray RT-qPCR miRs (n=93)
miR-204
Upregu-
lated
(49)miR-99a 
miR-100 
miR-137-3p 
miR-145a
Downregu-
lated
Cardiac 
tissue
CHD 
(n=30)
n=30 
normal 
samples
Gene ex-
pression 
microarray
RT-qPCR miR-145 
miR-182
miR-145
Downregu-
lated
(52)
Cardiac 
tissue
CHD 
(TOF, 
VSD, PA) 
(n=10)
n=11 
acyanotic 
cardiac 
defects
- RT-qPCR - miR-138 Upregu-
lated
(45)
Cardiac 
tissue
TOF 
(n=30)
n=10 
normal 
samples
Gene ex-
pression 
microarray
RT-qPCR
miR-1 
miR-19a 
miR-30a 
miR-30c 
miR-30d 
miR-30e 
miR-130a 
miR-130b 
miR-144 
miR-206
miR-1 
miR-206
Downregu-
lated
(36)
Cardiac 
tissue
Cyanotic 
CHD 
(n=10)
n=10 
acyanotic 
cardiac 
defects
- RT-qPCR - miR-184 Downregu-
lated
(53)
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Serum
TGA 
(n=26)
n=20 
healthy 
subjects
Microarray RT-qPCR miRs (n=23)
hsa-let-7e 
miR-16 
miR-18a 
miR-25 
miR-93 
miR-106a 
miR-144* 
miR-451 
miR-486-3p 
miR-486-5p 
miR-505*
Upregu-
lated
(47)
Serum
CHD 
(n=61)
n=20 
normal 
individuals
- RT-qPCR - miR-873 Upregu-
lated
(54)
Serum
Cyanotic 
CHD 
(n=32)
n=20 
acyanotic 
CHD 
individuals
- RT-qPCR - miR-182 Downregu-
lated
(55)
Plasma
VSD 
(n=20)
n=15 
VSD-free 
partici-
pants
Microarray RT-qPCR miRs (n=36)
miR-498
Upregu-
lated
(40)
hsa-let-7e-5p 
miR-155-5p 
miR-222-3p 
miR-379-5p 
miR-409-3p 
miR-433 
miR-487b
Downregu-
lated
Plasma
CHD 
(ASD, 
VSD, 
AVSD) 
(n=26)
n=27 
healthy 
children
miRNA 
PCR Array
RT-qPCR miRs 
(n=84)
hsa-let-7a 
hsa-let-7b 
miR-486
Upregu-
lated
(37)
Maternal 
serum
CHD 
(ASD, 
VSD, TOF) 
(n=30)
n=30 
normal 
fetuses
SOLiD 
sequencing RT-qPCR
miRs 
(n=11)
miR-19b 
miR-22 
miR-29c 
miR-375
Upregu-
lated
(42)
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To date, especially the common and/or severe 
CHDs have been studied extensively by miR ex-
pression profiling. VSD, as a discontinuation in 
the septal wall between left and right ventricles, 
accounts for approximately 20-40% of CHDs (Fig. 
1b) (40). Large defects lead to severe heart fail-
ure requiring urgent surgical intervention, while 
smaller ones may be asymptomatic and close 
spontaneously. The more severe forms can re-
sult in left-to-right shunt with consecutive left 
ventricle overload and pulmonary hypertension. 
Although its embryology and pathology have 
been clarified, its etiology remains unknown. 
After initial microarray screening, Li et al (41) 
compared the expression of a set of 25 candidate 
miRs in heart tissues of patients with VSD and 
healthy controls by qRT-PCR. They found that 
miR-1-1 expression was decreased in patient 
samples and associated with the increased level 
of its target genes, GJA1 and SOX9. The miR-181c 
overexpression, linked with the downregulation 
of BMPR2 gene, was identified as well. Later on, 
another research group reported for the first 
time circulating miR profiles for patients with 
VSD with upregulation of miR-498 and downreg-
ulation of hsa-let-7e-5p, miR-155-5p, miR-222-
3p, miR-379-5p, miR-409-3p, miR-433 and miR-
487b in plasma samples of patients (40). Zhu et 
al hypothetize that miRs in maternal serum can 
be used as biomarkers for the prenatal detection 
of fetal CHD in early pregnancy. They analyzed 
miR profiles in serum samples from pregnant 
women, who had fetuses with ASD, VSD or TOF 
and from women with normal pregnancies. They 
identified significantly higher expression of miR-
19b and miR-29c in case of VSD and upregula-
tion of miR-22 and miR-375 in TOF. Results of this 
study raised the possibility of using miRs in the 
maternal serum for early diagnosis of fetal car-
diac disorders as noninvasive biomarkers (42). 
However, because of the limitations of the study, 
further research is required to confirm the use-
fulness of miRs in the clinical practice for prena-
tal diagnosis of CHD.
There are much less data on the expression pro-
file of miRs in congenital ASD (Fig. 1c). In a more 
recent study Song and colleagues (37) identified 
significant upregulation of hsa-let-7a, hsa-let-
7b and miR-486 in children with ASD, VSD and 
AVSD. The hsa-let-7a and hsa-let-7b were spe-
cifically overexpressed in ASD cases supporting 
their hypothesis that specific miRs are associ-
ated with specific types of CHD. Similar expres-
sion profiles of hsa-let-7a and hsa-let-7b were 
detected in mothers of ASD children. Based on 
their results, not only do these miRs have diag-
nostic but also predicting roles for CHD risk in 
offspring.
*ASD: atrial septal defect, AVSD: atrioventricular septal defect, CHD: congenital heart disease, HLHS: hypoplastic left 
heart syndrome, miRs: microRNAs, PA: pulmonary atresia, RT-qPCR: reverse transcription-quantitative polymerase 
chain reaction, TGA: transposition of the great arteries, TOF: tetralogy of Fallot, VSD: ventricular septal defect.
Venous 
blood
TOF 
(n=37)
n=15 
healthy 
controls
Microarray RT-qPCR miRs 
(n=49)
miR-183-5p 
miR-421 
miR-625-5p 
miR-1233-3p
Upregu-
lated
(11)miR-140-3p 
miR-142-5p 
miR-181d-5p 
miR-206 
miR-339-5p
Downregu-
lated
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Figure 1 Altered expression of  miRs in CHDs*
a.) b.)
c.) d.)
e.) f.)
1
2
3
4
miR-19b
miR-29c
miR-181c
miR-195
miR-498
hsa-let-7e-5p
miR-1-1
miR-17-92
miR-133
miR-155-5p
miR-222-3p
miR-379-5p
miR-409-3p
miR-433
miR-487b
Ventricular Septal Defect
hsa-let-7a
hsa-let-7b
miR-486
Atrial Septal Defect
miR-22
miR-138
miR-222
miR-375
miR-421
miR-424/424*
miR-1
miR-206
miR-940
hsa-let-7e
miR-16
miR-18a
miR-25
miR-93
miR-106a
miR-144*
miR-451
miR-486-3p
miR-486-5p
miR-505*
Aorta(transposed) Hypoplastic Left Heart Syndrome 
miR-204
miR-208
miR-30
miR-99a
miR-100
miR-137-3p
miR-145a
miR-378
Pulmonary artery(transposed)
Normal heart
Tetralogy of Fallot
1
2
3
4
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TOF (Fig. 1d) is the most common form of cya-
notic CHD that represents 5-8% of all CHDs (43). 
It is characterized by: 1) pulmonary outflow 
tract obstruction; 2) VSD; 3) overriding aor-
tic root; and 4) right ventricular hypertrophy. 
Without surgery, patients have poor progno-
sis and follow-up studies show that even after 
repair of TOF they have a higher risk for heart 
failure. Despite its prevalence and clinical sig-
nificance, the underlying mechanism is poorly 
understood.
More recently, miRs have been investigated as 
etiological factors in the pathogenesis of TOF. 
O’Brien and colleagues (10) examined expres-
sion patterns of miRs in right ventricular myo-
cardium from infants with nonsyndromic TOF 
compared to infants with normally developing 
heart. Microarray analysis revealed that the lev-
els of 61 miRs significantly changed, especially 
miR-1275, miR-27b, miR-421, miR-1201 and 
miR-122, moreover the levels of expressions 
were similar to those in the fetal myocardium. 
Potential targets of miRs with altered expres-
sion were concentrated in gene networks criti-
cal to cardiac development. Subsequently, this 
group performed a follow-up study focusing on 
miR-421 by under- and overexpressing of miR-
421 on primary cells from ventricular myocar-
dium of TOF heart.
The authors found an inverse correlation be-
tween expression of miR-421 and SOX4 that is 
a key regulator of the Notch signaling pathway, 
which suggests the association of miR-421 with 
TOF (44). He et al (45) studied miR-138 expres-
sion in myocardial samples from patients with 
cyanotic TOF and identified a two-fold increase 
compared to patients with acyanotic CHD. 
Based on studies from Liang and colleagues 
(46) miR-940 is the most downregulated miR 
in myocardium from patients with TOF among 
the identified 75 dysregulated miRs. Zhang et 
al (30) applied microarray analysis to identify 
deregulation of miRs in right ventricular out-
flow tract tissue in infants with TOF. They found 
18 miRs with significantly altered expression, 
among which miR-424/424* and miR-222 were 
shown to affect cardiomyocyte proliferation 
and differentiation. MiR target gene network 
analysis showed that 16 of the 18 miRs targeted 
97 genes involved in heart development. 
Abnormal expression of connexin 43 (Cx43) has 
been documented in conotruncal anomalies al-
though the underlying mechanism is unknown. 
Wu and colleagues (36) investigated the poten-
tial role of miRs in altered expression of Cx43 
in myocardium samples of patients with TOF. 
They showed that miR-1 and miR-206 were sig-
nificantly decreased in the TOF patients as com-
pared with controls, which may cause upregula-
tion of Cx43 protein synthesis and suggest the 
role of these miRs in the pathogenesis of TOF.
Little is known about the expression profile of 
miRs in CHD with systemic right ventricle. In 
patients with TGA (Fig. 1e) after atrial switch 
*Figure 1 - Legend 
a) normal heart structure 
b) Ventricular Septal Defect (VSD): a hole in the wall between the lower chambers of the heart (the ventricles) 
c) Atrial Septal Defect (ASD): a hole in the wall between the upper chambers of the heart (the atria) 
d) Tetralogy of Fallot (TOF): a combination of four heart defects that are: 1. ventricular septal defect, 2. pulmonary 
stenosis, 3. right ventricular hypertrophy, 4. overriding aorta 
e) Transposition of the Great Arteries (TGA): the two major arteries (aorta and pulmonary artery) that carry blood 
away from the heart are switched (transposed) 
f) Hypoplastic Left Heart Syndrome (HLHS): a combination of: 1. underdeveloped left ventricle, 2. hypoplastic aorta, 3. 
atrial septal defect, 4. patent ductus arteriosus.
↑ Upregulation ↓ Downregulation
References: (10-12, 30, 36, 37, 40-42, 44-47, 49).
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operation, late systemic right ventricular dys-
function develops. Lai et al (47) tested the circu-
lating miR expression profile in these patients. 
They found that 23 miRs were upregulated, 11 
were validated to be increased in patients com-
pared with controls. MiR-18a and miR-486-5p 
expression signature correlated negatively with 
systemic ventricular contractility.
HLHS (Fig. 1f) represents 2% to 9% of CHDs 
and accounts for 23% of neonatal deaths. 
Characteristics of HLHS include varying degrees 
of hypoplasia of the left ventricle, mitral valve 
and aortic valve atresia/stenosis, and hypopla-
sia of the ascending aorta. This is one of the 
most serious cardiac malformation and leads 
to death in the newborn period without treat-
ment. Nowadays as a result of surgical palliative 
techniques a five-year survival can be reached 
in more than half the cases (48). Sucharov et 
al (49) investigated the miR expression in the 
right ventricle myocardium of HLHS patients. 
They found that pediatric HLHS population has 
a unique miR profile, and some miRs (miR-100, 
miR-145a, miR-99a, miR-137-3p, miR-204) are 
modulated by changes in volume loading of the 
right ventricle. Biostatistical analysis revealed 
that target genes of these miRs are important 
for cardiac development and disease.
The most common genetic defect leading to CHD 
is the trisomy 21 in Down syndrome. Five miRs 
are overexpressed in Down syndrome, miR-99a, 
hsa-let-7c, miR-125-b2, miR-155 and miR-802, 
all of them are located on chromosome 21 (50).
Patients with DiGeorge syndrome, which is the 
most common microdeletion syndrome, have 
heterogeneous phenotype including CHD, im-
munodeficiency and hypocalcemia. The genetic 
cause is the deletion of 22q11.2 region includ-
ing TBX1, which is essential in normal cardiac 
development. The DGCR8 gene encodes a cru-
cial component of the RNA induced silencing 
complex (RISC), necessary for miR biogenesis. 
Haploinsufficiency of this complex leads to im-
paired miR expression and development of CHD 
(51).
CONCLUSION
CHDs account for a significant part of cardio-
vascular diseases, perinatal morbidity and mor-
tality. Improved survival of children with CHD 
has led to high number of adult patients facing 
multiple challenges throughout their lifetime. 
Despite our increasing knowledge on the ge-
netic basis and signaling pathways involved in 
cardiac development, there are still huge gaps 
that require further examination.
In the cardiovascular research field, numerous 
studies demonstrated that miRs are required 
for proper heart development and function. 
Characteristic expression profiles of miRs have 
specific and generalized effects on cell signaling 
pathways associated with CHD.
MiRs are attractive diagnostic and prognostic 
biomarkers as they remain stable in bodily fluids 
and avoid RNA degrading enzymes and hereby 
may provide an additional diagnostic tool to as-
sess heart disease.
According to recent reports miRs can serve as 
noninvasive biomarkers for the extent of myo-
cardial damage and the postoperative clinical 
course of pediatric patients with CHDs follow-
ing surgery.
Despite the results having been reported in the 
past decade, the exact role of miRs in CHDs is 
still unclear. Large-scale studies are needed to 
provide a better understanding of the molecu-
lar interactions causing CHD.
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